Jensen BV - Search Results

1

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.

Kümler I, Sørensen PG, Palshof J, Høgdall E, Skovrider-Ruminski W, Theile S, Fullerton A, Nielsen PG, Jensen BV, Nielsen DL. Kümler I, et al. Among authors: jensen bv. Cancer Chemother Pharmacol. 2019 Jan;83(1):169-178. doi: 10.1007/s00280-018-3720-7. Epub 2018 Nov 8. Cancer Chemother Pharmacol. 2019. PMID: 30406838 Free PMC article. Clinical Trial.

2

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.

Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Ryberg M, et al. Among authors: jensen bv. J Clin Oncol. 1998 Nov;16(11):3502-8. doi: 10.1200/JCO.1998.16.11.3502. J Clin Oncol. 1998. PMID: 9817267

3

Angiotensin converting enzyme inhibitors for cancer treatment?

Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Lindberg H, et al. Among authors: jensen bv. Acta Oncol. 2004;43(2):142-52. doi: 10.1080/02841860310022346. Acta Oncol. 2004. PMID: 15163162 Review.

4

Serum YKL-40, a new prognostic biomarker in cancer patients?

Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Johansen JS, et al. Among authors: jensen bv. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202. doi: 10.1158/1055-9965.EPI-05-0011. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16492905 Review.

5

Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.

Nielsen DL, Pfeiffer P, Jensen BV. Nielsen DL, et al. Among authors: jensen bv. Acta Oncol. 2006;45(8):1137-8. doi: 10.1080/02841860600871764. Acta Oncol. 2006. PMID: 17118853 No abstract available.

6

Anthracycline-induced chronic cardiotoxicity and heart failure.

Appel JM, Nielsen D, Zerahn B, Jensen BV, Skagen K. Appel JM, et al. Among authors: jensen bv. Acta Oncol. 2007;46(5):576-80. doi: 10.1080/02841860601156165. Acta Oncol. 2007. PMID: 17562433 Review.

7

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.

Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, Jensen BV. Pfeiffer P, et al. Among authors: jensen bv. Acta Oncol. 2007;46(5):697-701. doi: 10.1080/02841860601009455. Acta Oncol. 2007. PMID: 17562448

8

Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.

Nielsen DL, Pfeiffer P, Jensen BV. Nielsen DL, et al. Among authors: jensen bv. Ann Oncol. 2009 Apr;20(4):798. doi: 10.1093/annonc/mdp040. Epub 2009 Mar 2. Ann Oncol. 2009. PMID: 19254943 Free article. No abstract available.

9

Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.

Appel JM, Jensen BV, Nielsen DL, Ryberg M, Zerahn B. Appel JM, et al. Among authors: jensen bv. Int J Cardiovasc Imaging. 2010 Feb;26(2):217-23. doi: 10.1007/s10554-009-9518-2. Epub 2009 Oct 13. Int J Cardiovasc Imaging. 2010. PMID: 19823942

10

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

Qvortrup C, Jensen BV, Jorgensen TL, Nielsen D, Bjerregaard JK, Pfeiffer P. Qvortrup C, et al. Among authors: jensen bv. Acta Oncol. 2010 Aug;49(6):833-6. doi: 10.3109/0284186X.2010.482104. Acta Oncol. 2010. PMID: 20615171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page